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II  Guideline Application
=========================

Purpose and objectives
----------------------

The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer. The S3 guideline provides important information and support for the planned organized screening for cervical cancer in Germany.

The old German-language S2k guideline "Prevention, Diagnosis and Therapy of HPV Infections and Preinvasive Lesions of the Female Genitalia" was consulted, and the new guideline focused on those aspects which deal with the cervix. Guideline recommendations on primary prevention were taken from the updated German-language S3 guideline "082/002 Vaccination to Prevent HPV-associated Neoplasias" and supplemented with additional information about the impact of HPV vaccination on screening. The German-language S3 guideline "032/033OL Cervical Cancer: Diagnosis, Treatment and Follow-up" published in 2014 covers all aspects of invasive cervical cancer.

Targeted areas of patient care
------------------------------

This S3 guideline on the prevention of cervical cancer presents various aspects of the prevention of cervical cancer and the diagnosis, treatment and follow-up of cervical cancer including high-grade preinvasive lesions. The main priorities of the guideline were analyzing existing data in order to optimize screening strategies for cervical cancer by determining the optimal test procedures, organizations, investigative algorithms and treatments, and considering how best to encourage women who previously refused to attend screening to participate in the program. In addition, the guideline considered the impact of HPV vaccination on screening strategies for cervical cancer.

Target patient group
--------------------

This S3 guideline is aimed at all women aged 20 and above.

Target user groups/target audience
----------------------------------

The recommendations of the guideline are addressed to all physicians and professionals involved in screening for cervical cancer, particularly gynecologists, pathologists and cytologists as well as all healthcare professionals working in dysplasia outpatient clinics and centers.

Other target groups include:

-   scientific medical societies and professional associations which are involved in screening for cervical cancer,

-   womenʼs advocacy groups (womenʼs health organizations, patient and self-help organizations),

-   quality assurance organizations and similar projects on national and federal state levels,

-   healthcare policy institutions and decision-makers at national and federal state levels,

-   payers,

-   the general public to inform them about what constitutes good medical practice.

Adoption and period of validity
-------------------------------

This guideline is valid from 31 December 2017 through to 31 December 2020. Because of the contents of the guideline, this period of validity is only an estimate. The guideline may need to be updated if new scientific evidence appears or the methodology used in the guideline is developed further. Moreover, the key statements and recommendations of the guideline should be subjected to regular editorial checks, and the contents of the guideline should be regularly reviewed.

III  Methodology
================

Basic principles
----------------

The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches. This guideline is classified as: S3.

Grading of evidence
-------------------

The GRADE (GRADE = Grading of Recommendations Assessment, Development and Evaluation) system developed by the GRADE Working Group [@R8287722-1] ( [www.gradeworkinggroup.org](www.gradeworkinggroup.org) ) was used to evaluate the quality of evidence of the studies identified and used for this guideline ( [Table 2](#TB8287722-2){ref-type="table"} ).

###### 

**Table 2**  Grading of the quality of evidence based on the GRADE system.

  GRADE              Beschreibung                                                                                                                                                                                  Symbol
  ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------
  High quality       *"We are very confident that the true effect lies close to that of the estimate of the effect."*                                                                                              ⊕⊕⊕⊕
  Moderate quality   *"We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different."*   ⊕⊕⊕⊖
  Low quality        *"Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect."*                                                         ⊕⊕⊖⊖
  Very low quality   *"We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect."*                                               ⊕⊖⊖⊖

Grading of recommendations
--------------------------

The methodology of the Oncology Guidelines Program requires guideline authors to assign a level of recommendation to each recommendation which indicates the strength of the recommendation. The strength of each recommendation is agreed upon in a formal consensus process which requires structured consensus conferences [@R8287722-2] . (Details are available in the German-language Guideline Report.) As part of this process, the mandate holders with voting rights formally voted on the recommendations in this guideline.

This guideline includes information on the grading of the evidence of the underlying studies used for all evidence-based Statements and Recommendations and additionally shows the strength of each recommendation (level of recommendation). In accordance with the AWMF Guidance Manual [@R8287722-2] , this guideline differentiates between three strengths or levels of recommendation, and the respective level of recommendation is reflected by the syntax used in the recommendation ( [Table 3](#TB8287722-3){ref-type="table"} ).

###### 

**Table 3**  Level of recommendation.

  Level of recommendation   Description             Syntax
  ------------------------- ----------------------- --------
  A                         Strong recommendation   must
  B                         Recommendation          should
  0                         Open recommendation     may

The decision criteria used to determine the level of recommendation are explained in the German-language Guideline Report for this guideline.

Statements
----------

Statements are expositions or explanations of specific facts, circumstances, or problems, with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on study results or expert opinions ( [Table 4](#TB8287722-4){ref-type="table"} ).

###### 

**Table 4**  Level of consensus.

  Level of consensus   Extent of agreement in percent
  -------------------- -----------------------------------------------------
  Strong consensus     \> 95% of participants entitled to vote agree
  Consensus            \> 75 -- 95% of participants entitled to vote agree
  Majority agreement   \> 50 -- 75% of participants entitled to vote agree
  No consensus         \< 50% of participants entitled to vote agree

Expert consensus (EC)
---------------------

Statements/Recommendations which were issued based on the expert consensus of the guideline authors are identified as being based on expert consensus. No symbols or letters are used to grade the level of expert consensus; the respective level of consensus is demonstrated by the syntax used (must/should/may) in accordance with the differentiation described in [Table 3](#TB8287722-3){ref-type="table"} .

IV  Guideline
=============

1  Differential diagnosis and evaluation algorithm
--------------------------------------------------

  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                                                                           GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------
  10.1.   If a cytological finding is classified as group IIa, the treating gynecologist should be informed that abnormal findings were detected previously (in the last 2 years) and that the patient should continue to be monitored. Additional work-ups to obtain a differential diagnosis are only indicated if they are necessary in the current constellation to avoid overtreatment.   EC

### 1.1  Indication for coloscopy depends on probability of CIN 3

  No.     Recommendations/Statements                                                                                                   GRADE
  ------- ---------------------------------------------------------------------------------------------------------------------------- -------
  10.2.   A colposcopic work-up should be done if the post-test probability for an average cumulative risk of CIN 3+ is 10% or more.   EC

### 1.2  What is the best diagnostic work-up strategy to investigate abnormal cytology

#### 1.2.1  Atypical squamous or glandular cells (Pap II-p, II-g)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                                                                                                                                                                                               GRADE   Sources
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  10.3.   If the findings obtained during organized cytological screening are classified as group II-p \~ ASC-US and II-g \~ AGUS, HR-HPV testing should be done after 6 months. If the HR-HPV test is positive, a colposcopic work-up should be done within 3 months.\                                            ⊕⊕⊕⊖\   [@R8287722-3] ,  [@R8287722-4] ,  [@R8287722-5] ,  [@R8287722-6] ,  [@R8287722-7] ,  [@R8287722-8] ,  [@R8287722-9] ,  [@R8287722-10] ,  [@R8287722-11] ,  [@R8287722-12] ,  [@R8287722-13] ,  [@R8287722-14] ,  [@R8287722-15] ,  [@R8287722-16] ,  [@R8287722-17] ,  [@R8287722-18] ,  [@R8287722-19] ,  [@R8287722-20] ,  [@R8287722-21] ,  [@R8287722-22] ,  [@R8287722-23] ,  [@R8287722-24] ,  [@R8287722-25] ,  [@R8287722-26] ,  [@R8287722-27] ,  [@R8287722-28] ,  [@R8287722-29] ,  [@R8287722-30] ,  [@R8287722-31] ,  [@R8287722-32] ,  [@R8287722-33] ,  [@R8287722-34] ,  [@R8287722-35] ,  [@R8287722-36] ,  [@R8287722-37] ,  [@R8287722-38] ,  [@R8287722-39] ,  [@R8287722-40] ,  [@R8287722-41] ,  [@R8287722-42] ,  [@R8287722-43] ,  [@R8287722-44] ,  [@R8287722-45] ,  [@R8287722-46] ,  [@R8287722-47] ,  [@R8287722-48] ,  [@R8287722-49] ,  [@R8287722-50] ,  [@R8287722-51] ,  [@R8287722-52] ,  [@R8287722-53]
          If the HPV test is negative, the patient should be followed up by HPV testing and cytology after 12 months.                                                                                                                                                                                              B       

  10.4.   If the findings obtained during organized cytological screening are classified as group II-p \~ ASC-US and II-g \~ AGUS, p16/Ki-67 testing may be carried out after 6 months. If the results of dual staining with p16/Ki-67 are positive, a colposcopic work-up should be performed within 3 months.\   ⊕⊖⊖⊖\   [@R8287722-43] ,  [@R8287722-54] ,  [@R8287722-55] ,  [@R8287722-56]
          If the results of dual staining with p16/Ki-67 are negative, the patient should be followed up with HPV testing and cytology after 12 months.                                                                                                                                                            0       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.2.2  Cytological suspicion of low-grade dysplasia (Pap IIID1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                       GRADE   Sources
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  10.5.   If the findings obtained during organized cytological screening are classified as group IIID1\~ LSIL, a diagnostic work-up based on HR-HPV testing should be carried out after 6 months. If the HR-HPV test is positive, a colposcopic work-up should be done within 3 months. If the HPV test is negative, the patient should be followed up with HPV testing and cytology after 12 months.                                                                                     ⊕⊕⊕⊖\   [@R8287722-4] ,  [@R8287722-5] ,  [@R8287722-8] ,  [@R8287722-10] ,  [@R8287722-13] ,  [@R8287722-17] ,  [@R8287722-23] ,  [@R8287722-26] ,  [@R8287722-27] ,  [@R8287722-28] ,  [@R8287722-29] ,  [@R8287722-31] ,  [@R8287722-32] ,  [@R8287722-35] ,  [@R8287722-39] ,  [@R8287722-41] ,  [@R8287722-42] ,  [@R8287722-43] ,  [@R8287722-45] ,  [@R8287722-46] ,  [@R8287722-47] ,  [@R8287722-48] ,  [@R8287722-49] ,  [@R8287722-51] ,  [@R8287722-52] ,  [@R8287722-53] ,  [@R8287722-57] ,  [@R8287722-58] ,  [@R8287722-59] ,  [@R8287722-60] ,  [@R8287722-61] ,  [@R8287722-62] ,  [@R8287722-63] ,  [@R8287722-64] ,  [@R8287722-65] ,  [@R8287722-66] ,  [@R8287722-67] ,  [@R8287722-68]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           B       

  10.6.   If the findings obtained during organized cytological screening are classified as group IIID1\~ LSIL, a diagnostic work-up based on p16/Ki-67 testing should be done after 6 months. If the results of this dual staining with p16/Ki-67 are positive, the patient should be investigated further by colposcopy within 3 months. If the results of dual staining with p16/Ki-67 are negative, the patient should be followed up with HPV testing and cytology after 12 months.   ⊕⊖⊖⊖\   [@R8287722-43] ,  [@R8287722-55] ,  [@R8287722-56] ,  [@R8287722-68] ,  [@R8287722-69]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.2.3  Unclear cytological findings classified as Pap III-p, III-g, III-x

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------
  10.7.   a\) If the findings obtained during organized cytological screening are classified as group III-p, III-x, III-e or III-g, a diagnostic work-up based on either HR-HPV testing or p16/Ki-67 immunocytochemistry may be carried out within 3 months. If the HR-HPV test or the results of dual staining with p16/Ki-67 are positive, a colposcopic work-up should be done within 3 months. If the diagnostic tests are negative, the patient should be followed up with HPV testing and cytology after 12 months.\   EC
          b) If the findings obtained during organized cytological screening are classified as group III-x, III-e and III-g, an endometrium-specific work-up should be done to exclude endometrial neoplasia (vaginal ultrasound, hysteroscopy, fractionated curettage, etc.).                                                                                                                                                                                                                                               

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.2.4  Moderate and high-grade cytological abnormalities (Pap IIID2, Pap IVa, Pap IVb, Pap V)

  No.     Recommendations/Statements                                                                                                                                                                                    GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  10.8.   If the findings obtained during organized cytological screening are classified as group IIID2, IV a -- p, IV a -- g, IV b -- p, IV b -- g, V-p, V-g, V-e or V-x, diagnostic colposcopy must be carried out.   EC

### 1.3  What are the best diagnostic work-up strategies for patients with a positive HPV test at screening and aged \> 30 years?

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.      Recommendations/Statements                                                                                                                                                                                                                                GRADE   Sources
  -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  10.9.    If the results of an HPV test done as part of routine screening are positive, a diagnostic work-up using cytology should be carried out.                                                                                                                  ⊕⊕⊖⊖\   [@R8287722-70] ,  [@R8287722-71] ,  [@R8287722-72] ,  [@R8287722-73] ,  [@R8287722-74] ,  [@R8287722-75] ,  [@R8287722-76] ,  [@R8287722-77] ,  [@R8287722-78] ,  [@R8287722-79]
                                                                                                                                                                                                                                                                     B       

  10.10.   If the results of an HPV test done as part of routine screening are positive, a diagnostic work-up using p16/Ki-67 testing may be carried out.                                                                                                            ⊕⊖⊖⊖\   [@R8287722-72] ,  [@R8287722-73]
                                                                                                                                                                                                                                                                     0       

  10.11.   If the results of an HPV-16/18 test carried out as part of HPV-based screening are positive, a diagnostic work-up using colposcopy should be carried out.                                                                                                 ⊕⊖⊖⊖\   [@R8287722-77] ,  [@R8287722-79]
                                                                                                                                                                                                                                                                     B       

  10.12.   If the results of a routine screening HPV test are positive and the results of diagnostic cytology or the results of combined HPV and Pap screening are classified as group II-p or above, a diagnostic work-up using colposcopy should be carried out.   EC      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2  Colposcopy
-------------

### 2.1  Use of diagnostic colposcopy

  No.     Recommendations/Statements                                                                                                                                                                                                                                                 GRADE
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  11.1.   Colposcopy must not be used for screening.                                                                                                                                                                                                                                 EC
  11.2.   If there is a high suspicion of CIN 3+ or ACIS/adenocarcinoma (risk ≥ 10%\*), diagnostic colposcopy must be carried outto histologically confirm squamous and glandular atypia/neoplasia,to determine the surgical strategy.                                               EC
  11.3.   If the transformation zone is classified as Type 1 or Type 2 at diagnostic colposcopy, colposcopy-guided biopsies should be obtained from the highest-grade lesion(s); if the transformation zone is classified as Type 3, endocervical curettage should be carried out.   EC

### 2.2  Quality criteria for diagnostic colposcopy or dysplasia clinics

  No.     Recommendations/Statements                                                                                                                                                   GRADE
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  11.4.   Diagnostic colposcopy procedures must be carried out by a dysplasia clinic or dysplasia unit certified in accordance with the requirements of the DKG/DGGG/AGO/AG-CPC/EFC.   EC

3  Healthcare structures
------------------------

  No.     Recommendations/Statements                                                                                                                                                                                                                                                                    GRADE
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  12.1.   Around 50% of women in Germany participate annually in cancer screening ( *Krebsfrüherkennungsuntersuchung* , KFU) which has been recommended in Germany since 1971 and screens participants for cervical cancer. Around 70% of women participate in screening at least once every 3 years.   EC
  12.2.   In Germany, rates of participation in cervical cancer screening (KFU) are lower for women with a low socio-economic status and/or for women of advanced age.                                                                                                                                  EC
  12.3.   Organized screening with population-based invitations to attend screening and more stringent quality controls may result in more effective and more balanced screening in terms of the socio-economic status and the age of participants.                                                     EC

4  Strategy for non-participation in screening
----------------------------------------------

### 4.1  Letters of invitation

  No.     Recommendations/Statements                                                                                                                                                                                                                             GRADE   Sources
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------- ----------------------------------------------------------------------------------------
  13.1.   The repeated sending of letters of invitation to attend screening as part of an organized screening program results in an only marginal increase in participation rates among those women who have not previously participated in regular screening.   ⊕⊕⊖⊖    [@R8287722-80] ,  [@R8287722-81] ,  [@R8287722-82] ,  [@R8287722-83] ,  [@R8287722-84]

### 4.2  HPV self-collection

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                                                       GRADE   Sources
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  13.2.   The participation rates of women who did not participate in cancer screening despite receiving a letter of invitation can be doubled with HPV self-collection.   ⊕⊕⊕⊖\   [@R8287722-85] ,  [@R8287722-86] ,  [@R8287722-87] ,  [@R8287722-88] ,  [@R8287722-89] ,  [@R8287722-90] ,  [@R8287722-91] ,  [@R8287722-92] ,  [@R8287722-93] ,  [@R8287722-94]
                                                                                                                                                                           B       

  13.3.   Self-sampling should therefore be offered to these women (nonresponders).                                                                                        ⊕⊕⊕⊖\   [@R8287722-85] ,  [@R8287722-86] ,  [@R8287722-87] ,  [@R8287722-88] ,  [@R8287722-89] ,  [@R8287722-90] ,  [@R8287722-91] ,  [@R8287722-92] ,  [@R8287722-93] ,  [@R8287722-94]
                                                                                                                                                                           B       

  13.4.   HPV self-collection for screening must be reserved for those women who do not otherwise participate in cancer screening.                                         ⊕⊕⊕⊖\   [@R8287722-89] ,  [@R8287722-95] ,  [@R8287722-96] ,  [@R8287722-97] ,  [@R8287722-98] ,  [@R8287722-99] ,  [@R8287722-100] ,  [@R8287722-101] ,  [@R8287722-102] ,  [@R8287722-103] ,  [@R8287722-104] ,  [@R8287722-105] ,  [@R8287722-106] ,  [@R8287722-107] ,  [@R8287722-108] ,  [@R8287722-109] ,  [@R8287722-110] ,  [@R8287722-111] ,  [@R8287722-112] ,  [@R8287722-113] ,  [@R8287722-114] ,  [@R8287722-115] ,  [@R8287722-116] ,  [@R8287722-117] ,  [@R8287722-118] ,  [@R8287722-119] ,  [@R8287722-120] ,  [@R8287722-121] ,  [@R8287722-122] ,  [@R8287722-123] ,  [@R8287722-124] ,  [@R8287722-125] ,  [@R8287722-126] ,  [@R8287722-127]
                                                                                                                                                                           A       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5  Treatment
------------

### 5.1  Appropriate treatment methods for squamous and glandular cervical intraepithelial neoplasia

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               GRADE   Sources
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------- -------------------------------------------------------
  14.1.   Loop excision and laser excision are the methods of choice to treat squamous and glandular cervical intraepithelial neoplasia.                                                                                                                                                                                                                                                                                                                                                                                           ⊕⊖⊖⊖\   [@R8287722-128] ,  [@R8287722-129] ,  [@R8287722-130]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   A       

  14.2.   Cold-knife conization may be used as an alternative to treat glandular intraepithelial neoplasia.                                                                                                                                                                                                                                                                                                                                                                                                                        ⊕⊖⊖⊖\   [@R8287722-128]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   0       

  14.3.   After histological confirmation using punch biopsy, laser vaporization must only be used to treat CIN 1, CIN 2 or CIN 3 if all of the following conditions are met:the whole transformation zone can be visualized (T-Zone Type 1),there are no indications of any changes in the glandular epithelium,there are no indications of any invasive process,there are no discrepancies between cytological, colposcopic and histological assessments of the biology of any changes,the patient is not older than 50 years.   EC      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 5.2  Treatment under colposcopic control

  No.     Recommendations/Statements                                                                                          GRADE
  ------- ------------------------------------------------------------------------------------------------------------------- -------
  14.4.   Treatment, whether it consists of excision or ablative procedures, must be carried out under colposcopic control.   EC

### 5.3  Management of CIN

#### 5.3.1  Monitoring, testing or treatment for CIN 1

  No.     Recommendations/Statements                                                                                                                                                                                                  GRADE
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  14.5.   If CIN 1 is confirmed histologically, the initial approach must be to wait and see and re-evaluate the patient after 6 months\*.                                                                                            EC
  14.6.   If CIN 1 is accompanied by Pap smear results classified as group IVa or higher and the lesion cannot be adequately evaluated and extends into the endocervix, the endocervical canal must be evaluated by histopathology.   EC

#### 5.3.2  Monitoring or treatment for CIN 2

  No.     Recommendations/Statements                                                                                                                                                                                                                                                   GRADE
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  14.7.   If a histologically confirmed CIN 2 lesion can be evaluated in its entirety and the transitional area between squamous and columnar epithelium can be entirely visualized, the initial approach is to wait and see and re-examine the patient after 6 months\*.              EC
  14.8.   If the transitional area between squamous and columnar epithelium cannot be entirely visualized in a patient with a histologically confirmed CIN 2 lesion and/or at least one Pap smear was classified as IVa, the endocervical canal must be evaluated by histopathology.   EC

#### 5.3.3  Treatment for CIN 3

  No.     Recommendations/Statements                                          GRADE
  ------- ------------------------------------------------------------------- -------
  14.9.   A lesion confirmed histopathologically as CIN 3 must be resected.   EC

#### 5.3.4  Treatment recommendations for adolescents

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.      Recommendations/Statements                                                                                                                                                                                                                                                                                                                                              GRADE
  -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  14.10.   A conservative strategy must be used for women up to the age of 24 with histopathologically confirmed CIN 2 and can be used for women up to the age of 24 with histopathologically confirmed CIN 3, provided\                                                                                                                                                           EC
           the lesion can be evaluated colposcopically in its entirety, andit does not contain any atypical glandular components, andan invasive process can be excluded with a high degree of certainty.Treatment should be carried out if the CIN 2 persists for more than 24 months or the CIN 3 persists for more than 12 months or the lesion expands into the endocervix.\   
           Treatment must be tissue-sparing.\*                                                                                                                                                                                                                                                                                                                                     

  14.11.   Women up to the age of 24 with CIN 3 who are managed conservatively should be monitored by a certified dysplasia clinic (s. Chapter 2 Colposcopy).                                                                                                                                                                                                                      EC
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 5.3.5  Excision procedures vs. hysterectomy for cervical adenocarcinoma in situ (ACIS)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.      Recommendations/Statements                                                                                                                                 GRADE
  -------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  14.12.   The definitive histopathological diagnosis of ACIS (with the differential diagnosis excluding invasive adenocarcinoma) must be obtained by excision.\      EC
           Hysterectomy should be the definitive treatment for ACIS if the patient plans to have no more children.\                                                   
           If the patient wishes to have children, R0 resection must be carried out and the patient must be followed up using colposcopy, cytology and HPV testing.   

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 5.3.6  R0 resection and approach for R1 resection

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.      Recommendations/Statements                                                                                                                                                                                      GRADE
  -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  14.13.   The goal must be to achieve R0 resection of a CIN 3.                                                                                                                                                            EC

  14.14.   If the resection status after surgical excision of a CIN 3 is R1 and there is no suspicion of invasive cancer, the patient must attend a follow-up appointment after 6 months with cytology and HPV testing.\   EC
           If the findings at follow-up show that CIN 3 has persisted, the patient must be re-operated.                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6  Pregnancy
------------

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                                                                                                                                  GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  15.1.   The indications for colposcopy (and biopsy, if required) during pregnancy are the same as those for non-pregnant women.                                                                                                                     EC

  15.2.   During pregnancy, the investigation of abnormal cervical cancer screening results should be done by a DKG/AG-CPC-certified dysplasia clinic.                                                                                                EC

  15.3.   Endocervical curettage must not be performed during pregnancy.\                                                                                                                                                                             EC
          An endocervical smear extending deep into the endocervical canal should not be done during pregnancy.                                                                                                                                       

  15.4.   If the results of the investigation (obtained by cytology, colposcopy and histologically if necessary) exclude high-grade dysplasia and carcinoma, no further colposcopy and/or cytological investigations are required during pregnancy.   EC
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 6.1  Approach for CIN 2/CIN 3 and ACIS in pregnancy

  No.     Recommendations/Statements                                                                                                                                                                              GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  15.5.   Pregnant women with CIN 2/CIN 3 or ACIS must not be treated surgically if invasive cancer can be excluded with a high degree of certainty.                                                              EC
  15.6.   Pregnant women with CIN 2/CIN 3 or ACIS must be monitored regularly by colposcopy. The pregnant patient must be evaluated by colposcopy every three months.                                             EC
  15.7.   Excision to obtain histological confirmation is indicated in pregnant women if it is not possible to exclude invasive carcinoma by cytology, colposcopy and biopsy with any high degree of certainty.   EC

### 6.2  Birth procedure when CIN 2/3 is present

  No.     Recommendations/Statements                                                                   GRADE
  ------- -------------------------------------------------------------------------------------------- -------
  15.8.   The presence of CIN 2/CIN 3 must have no impact on the decision about the birth procedure.   EC

### 6.3  Obstetric complications after treatment for CIN

  No.      Recommendations/Statements                                                                                                                                                                                           GRADE
  -------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  15.9.    Excision procedures performed during pregnancy are associated with significant obstetric risks such as preterm birth. Previous excision procedures are also associated with higher risk in subsequent pregnancies.   EC
  15.10.   As cold-knife conization is associated with the highest obstetric risk, it must not be carried out in women who still wish to have children.                                                                         EC

7  Follow-up care
-----------------

### 7.1  Follow-up with HPV testing and cytology after treatment for CIN

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                            GRADE   Sources
  ------- ------------------------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  16.1.   Follow-up after treatment for CIN/ACIS must consist of examinations combining HPV testing and cytology.                               ⊕⊕⊖⊖\   [@R8287722-131] ,  [@R8287722-132] ,  [@R8287722-133] ,  [@R8287722-134] ,  [@R8287722-135] ,  [@R8287722-136] ,  [@R8287722-137] ,  [@R8287722-138] ,  [@R8287722-139] ,  [@R8287722-140] ,  [@R8287722-141] ,  [@R8287722-142] ,  [@R8287722-143] ,  [@R8287722-144] ,  [@R8287722-145] ,  [@R8287722-146]
                                                                                                                                                A       

  16.2.   Differential colposcopy should be performed if the findings at follow-up are abnormal (at least 1 of the test results is positive).   ⊕⊕⊖⊖\   [@R8287722-131] ,  [@R8287722-132] ,  [@R8287722-133] ,  [@R8287722-134] ,  [@R8287722-135] ,  [@R8287722-136] ,  [@R8287722-137] ,  [@R8287722-138] ,  [@R8287722-139] ,  [@R8287722-140] ,  [@R8287722-141] ,  [@R8287722-142] ,  [@R8287722-143] ,  [@R8287722-144] ,  [@R8287722-145] ,  [@R8287722-146]
                                                                                                                                                B       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 7.1.1  Time and duration of follow-up

  No.     Recommendations/Statements                                                                                                                                                                                                                            GRADE
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  16.3.   Follow-up examinations combining HPV testing and cytology should be performed at 6, 12 and 24 months after completing treatment. The patient must continue to participate in regular screening, even if the findings at follow-up are unremarkable.   EC

### 7.2  Importance of biomarkers during follow-up after treatment for CIN

#### 7.2.1  Resection margin as a predictor for recurrence of treated CIN

  No.     Recommendations/Statements                                                                                GRADE   Sources
  ------- --------------------------------------------------------------------------------------------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  16.4.   Follow-up after treatment for CIN/ACIS must consist of examinations combining HPV testing and cytology.   ⊕⊖⊖⊖    [@R8287722-134] ,  [@R8287722-135] ,  [@R8287722-136] ,  [@R8287722-147] ,  [@R8287722-148] ,  [@R8287722-149] ,  [@R8287722-150] ,  [@R8287722-151] ,  [@R8287722-152]

#### 7.2.2  Other biomarkers as predictors for recurrence of treated CIN 2/3 lesion

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/Statements                                                                                                        GRADE   Sources
  ------- --------------------------------------------------------------------------------------------------------------------------------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  16.5.   Biomarkers (5-type HPV mRNA, HPV type-specific persistence) must not be used to follow up patients treated for CIN 2/3 lesions.   ⊕⊖⊖⊖\   [@R8287722-134] ,  [@R8287722-137] ,  [@R8287722-151] ,  [@R8287722-153] ,  [@R8287722-154] ,  [@R8287722-155] ,  [@R8287722-156] ,  [@R8287722-157]
                                                                                                                                            A       

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

8  Complementary, alternative and integrative medicine
------------------------------------------------------

### 8.1  Alternative medical diagnostic methods

  No.     Recommendations/Statements                                                                                                                   GRADE
  ------- -------------------------------------------------------------------------------------------------------------------------------------------- -------
  17.1.   Alternative medical diagnostic methods must not be used to detect cervical dysplasia or establish a predisposition for cervical dysplasia.   EC

### 8.2  Alternative medical treatment

  No.     Recommendations/Statements                                        GRADE
  ------- ----------------------------------------------------------------- -------
  17.2.   Alternative medical treatments of dysplasia should be rejected.   EC

### 8.3  Complementary medical treatment

  No.     Recommendations/Statements                                                                                                         GRADE
  ------- ---------------------------------------------------------------------------------------------------------------------------------- -------
  17.3.   It is not possible to make any recommendations about complementary medical treatments because of the lack of meaningful studies.   EC

9  Patient education and information, dealing with psychological stress
-----------------------------------------------------------------------

### 9.1  Patient education and information given to women participating in cervical cancer screening

  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                             GRADE
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  18.1.   Information given to the women who participate in screening for cervical cancer must cover the following aspects:an explanation of the disease,the natural progression of infection with HPV and associated cell changes,the different HPV types,the risk factors for cervical cancer,the impact on the patientʼs partner(s),a description of the screening method,information about the benefits and harm of screening methods,information on the quality of the screening methods.   EC

### 9.2  Educating patients about their diagnosis, treatment options and follow-up care

  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                    GRADE
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  18.2.   The information given to women with findings at screening which require further investigation must include the following:the findingsthe differential diagnosisthe treatment optionsthe treatment goalsthe duration of the different treatments and how they are carried outthe necessity of regular follow-up appointments   EC

10  Cost-effectiveness
----------------------

  No.     Recommendations/Statements                                                                                                                                                                                                                                                                                                                             GRADE   Sources
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------- ----------------------------------------------
  19.1.   HPV-based screening performed every 3 years has a relatively favorable cost-effectiveness ratio. Compared to annual cytology-based screening, HPV-based screening has a similar expected benefit and a lower expected harm (e.g. surgical interventions, colposcopies, psychological stress caused by abnormal findings and follow-up examinations).   ⊕⊖⊖⊖    \[cf. Guideline Report and Evidence Report\]
  19.2.   In Germany, HPV-based screening carried out at intervals of every 3 -- 5 years is considered to be cost-effective. HPV-based screening carried out at intervals of every 2 years has a less favorable cost-effectiveness ratio. Annual screening significantly increases costs without generating a significant additional benefit.                    ⊕⊖⊖⊖    [@R8287722-158]
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Prävention des Zervixkarzinoms. Leitlinie der DGGG und DKG (S3-Level, AWMF-Register-Nummer 015/027OL, Dezember 2017) -- Teil 2 mit Abklärung, Therapie und Nachbetreuung

**Ziele** Seit 1971 erfolgt in Deutschland die jährliche, opportunistische Früherkennungsuntersuchung des Zervixkarzinoms. Durch die Etablierung dieser S3-Leitlinie wird zum einen eine wichtige Forderung des Nationalen Krebsplans zum Zervixkarzinom-Screening erfüllt. Zum anderen kann die S3-Leitlinie wesentliche Informationen und Hilfestellungen für das geplante organisierte Zervixkarzinomscreening in Deutschland geben.

**Methoden** Mit finanzieller Unterstützung durch die Deutsche Krebshilfe wurden durch 21 Fachgesellschaften evidenzbasierte Statements und Empfehlungen (GRADE-System) zu Screening, Management und Behandlung von Zervixkarzinom-Vorstufen erarbeitet. Zwei unabhängige wissenschaftliche Institute haben systematische Reviews für diese Leitlinie erarbeitet.

**Empfehlungen** Der zweite Teil dieser Kurzzusammenfassung behandelt u. a. Abklärung, Therapie und Nachbetreuung zervikaler Dysplasien. Im Hinblick auf Nichtteilnehmerinnen am Screening empfiehlt die Leitliniengruppe erneute Einladungsschreiben oder eine HPV-Selbstabnahme. Ab einer Zytologie von Pap II-p in Kombination mit einem positiven HPV-Befund sollte eine Kolposkopie zur weiteren Abklärung durchgeführt werden, ebenso bei einem positiven HPV 16 oder HPV 18 Screening Test. Ein alleiniger auffälliger Pap-Abstrich sollte eine Triage mittels HPV-Test oder p16/Ki67 Dual-stain zur Folge haben.

Zervixkarzinom

zervikale intraepitheliale Neoplasie (CIN)

zervikale Präkanzerosen
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I  Leitlinieninformationen
==========================
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Zitationsformat
===============
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Leitliniendokumente
===================

Die vollständige Langversion mit einer Aufstellung der Interessenkonflikte aller Autoren und eine Kurzversion können auf der Homepage der AWMF eingesehen werden: <https://www.awmf.org/leitlinien/detail/ll/015-027OL.html> oder [www.leitlinienprogramm-onkologie.de](www.leitlinienprogramm-onkologie.de)

Leitliniengruppe
================

Federführende Fachgesellschaft bei der Leitlinienerstellung ist die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG, Mandatsträger Univ.-Prof. Dr. Peter Hillemanns, Hannover). Herausgeber der Leitlinie ist das Onkologische Leitlinienprogramm. Jede beteiligte Fachgesellschaft hat einen Mandatsträger benannt, der schriftlich vom jeweiligen Vorstand bestätigt wurde. In [Tab. 1](#TB8287722DE-1){ref-type="table"} sind die an der Leitlinienerstellung beteiligten Fachgesellschaften und andere Organisationen sowie deren mandatierte Vertreter aufgeführt. Stimmberechtigt in den Abstimmungsprozessen (Konsensusverfahren) waren nur die von den teilnehmenden Fachgesellschaften und Organisationen benannten Mandatsträger nach Offenlegung und Ausschluss von Interessenkonflikten. Die Leitlinie wurde unter direkter Beteiligung einer Patientenvertreterin erstellt. Frau Marion Gebhardt (Frauenselbsthilfe nach Krebs e. V.) war von Beginn an in die Erstellung der Leitlinie eingebunden und nahm mit eigenem Stimmrecht an den Konsensuskonferenzen teil.

###### 

**Tab. 1**  Beteiligte Fachgesellschaften und andere Organisationen.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  beteiligte Fachgesellschaften und Organisationen                                                         Mandatsträger
  -------------------------------------------------------------------------------------------------------- -----------------------------------------------
  Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG)                                            Christian Dannecker

  Deutsche Gesellschaft für Epidemiologie (DGEpi)                                                          Stefanie Klug

  Deutsche Gesellschaft für Virologie e. V. (GfV)                                                          Thomas Iftner

  Deutsche Gesellschaft für Pathologie e. V. (DGP)                                                         Thomas Löning\
                                                                                                           Lars Horn (Stellvertreter)\
                                                                                                           Dietmar Schmidt (Stellvertreter)

  Deutsche STI-Gesellschaft e. V. (DSTIG)                                                                  Hans Ikenberg

  Deutsche Gesellschaft für Zytologie (DGZ)\*                                                              Heinrich Neumann (bis 14.08.2013)\
                                                                                                           Volker Schneider (bis 12.05.2014)

  Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS)              Uwe Siebert\
                                                                                                           Willi Sauerbrei (Stellvertreter)

  Arbeitsgemeinschaft für gynäkologische Onkologie der DKG, AGO                                            Matthias Beckmann

  Frauenselbsthilfe nach Krebs e. V.                                                                       Marion Gebhardt\
                                                                                                           Heidemarie Haase (Stellvertreterin)

  Berufsverband der Frauenärzte e. V., BVF\*                                                               Manfred Steiner\
                                                                                                           Ulrich Freitag (Stellvertreter)

  Arbeitsgemeinschaft Leitender Ärztinnen und Ärzte in der Frauenheilkunde und Geburtshilfe e. V. (BLFG)   Michael Friedrich

  Berufsverband zytologisch tätiger Ärzte in Deutschland e. V. (AZÄD)\*                                    Klaus Neis\
                                                                                                           Bodo Jordan (Stellvertreter)

  Arbeitsgemeinschaft Zervixpathologie und Kolposkopie der DGGG\*                                          Wolfgang Kühn\
                                                                                                           Michael Menton (Stellvertreter)

  Arbeitsgemeinschaft Prävention und integrative Onkologie (PRIO), DKG Sektion B                           Karsten Münstedt

  HPV-Management-Forum (Paul-Ehrlich-Gesellschaft für Chemotherapie PEG e. V.)                             Achim Schneider\
                                                                                                           Andreas Kaufmann (Stellvertreter)

  Studiengruppe Kolposkopie e. V.                                                                          K. Ulrich Petry

  Arbeitsgemeinschaft für Infektionen und Infektionsimmunologie der DGGG (AGII)                            Axel P. A. Schäfer

  DKFZ                                                                                                     Magnus von Knebel-Doeberitz (bis 25.06.2013)\
                                                                                                           Michael Pawlita

  **internationale Organisationen**                                                                        

  Arbeitsgemeinschaft für gynäkologische Onkologie und Brustgesundheit (AGO) der (SGGG)\*\*                Mathias Fehr

  Arbeitsgemeinschaft für gynäkologische Onkologie (AGO) der (OEGGG)\*\*                                   Christoph Grimm\
                                                                                                           Olaf Reich (Stellvertreter)

  European Society of Gynaecological Oncology (ESGO)\*\*\*                                                 Rainer Kimmig\
                                                                                                           Martin Heubner (Stellvertreter)
  --------------------------------------------------------------------------------------------------------------------------------------------------------

II  Leitlinienverwendung
========================

Fragen und Ziele
================

Durch die Etablierung dieser S3-Leitlinie wird zum einen eine wichtige Forderung des Nationalen Krebsplans zum Zervixkarzinom-Screening erfüllt. Zum anderen kann die S3-Leitlinie wesentliche Informationen und Hilfestellungen für das geplante organisierte Zervixkarzinomscreening in Deutschland geben.

Die Ziele der alten S2k-Leitlinie „Prävention, Diagnostik und Therapie der HPV-Infektion und präinvasiver Läsionen des weiblichen Genitale" werden fokussiert auf den Gebärmutterhals. Leitlinienempfehlungen zur primären Prävention werden aus der aktualisierten S3-Leitlinie „082/002 Impfprävention HPV-assoziierter Neoplasien" übernommen, allerdings ergänzt bezüglich der Auswirkungen, die eine HPV-Impfung auf das Screening haben kann. Die 2014 fertig gestellte S3-Leitlinie „032/033OL Zervixkarzinom: Diagnostik, Therapie und Nachsorge" umfasst alle Aspekte des invasiven Zervixkarzinoms.

Versorgungsbereich
==================

Diese S3-Leitlinie zur Prävention des Zervixkarzinoms legt die Aspekte zur Prävention des Zervixkarzinoms und zu Diagnostik, Therapie und Nachsorge bis einschließlich der hochgradigen präinvasiven Läsionen dar. Wesentliche Ziele der Leitlinie sind die Analyse der vorhandenen Daten nach Optimierung der Krebsfrüherkennung des Zervixkarzinoms hinsichtlich der Testverfahren, der Organisationsstruktur, des Abklärungsalgorithmus, der Therapie und die Klärung der Frage, wie die Vorsorgeverweigererinnen zur Teilnahme stimuliert werden können. Daneben gilt es, die Auswirkung der HPV-Impfung auf die Krebsfrüherkennung-Strategie zu untersuchen.

Patienten/innenzielgruppe
=========================

Diese S3-Leitlinie richtet sich an alle Frauen ab einem Alter von 20 Jahren.

Anwenderzielgruppe/Adressaten
=============================

Die Empfehlungen der Leitlinie richten sich an alle Ärzte und Angehörigen von Berufsgruppen, die mit der Früherkennung des Zervixkarzinoms befasst sind, vor allem an Gynäkologen, Pathologen bzw. Zytologen, sowie alle Mitarbeiter von Dysplasiesprechstunden und -zentren.

Weitere Adressaten sind:

-   medizinisch-wissenschaftliche Fachgesellschaften und Berufsverbände, die mit der Früherkennung des Zervixkarzinoms befasst sind,

-   Interessenvertretungen von Frauen (Frauengesundheitsorganisationen, Patienten- und Selbsthilfeorganisationen),

-   Qualitätssicherungseinrichtungen und -projekte auf Bundes- und Länderebene,

-   gesundheitspolitische Einrichtungen und Entscheidungsträger auf Bundes- und Länderebene,

-   Kostenträger,

-   die Öffentlichkeit zur Information über gute medizinische Vorgehensweise.

Verabschiedung und Gültigkeitsdauer
===================================

Diese Leitlinie besitzt eine Gültigkeitsdauer vom 31.12.2017 bis 31.12.2020. Diese Dauer ist aufgrund der inhaltlichen Zusammenhänge geschätzt. Der Bedarf zur Aktualisierung der Leitlinie ergibt sich zudem aus der Existenz neuer wissenschaftlicher Erkenntnisse und der Weiterentwicklung in der Leitlinienmethodik. Zudem ist in regelmäßigen Abständen eine redaktionelle und inhaltliche Prüfung und Überarbeitung der Kernaussagen und Empfehlungen der Leitlinie erforderlich.

III  Leitlinienmethodik
=======================

Grundlagen
==========

Die Methodik zur Erstellung dieser Leitlinie wird durch die Vergabe der Stufenklassifikation vorgegeben. Das AWMF-Regelwerk (Version 1.0) gibt entsprechende Regelungen vor. Es wird zwischen der niedrigsten Stufe (S1), der mittleren Stufe (S2) und der höchsten Stufe (S3) unterschieden. Die niedrigste Klasse definiert sich durch eine Zusammenstellung von Handlungsempfehlungen, erstellt durch eine nicht repräsentative Expertengruppe. Im Jahr 2004 wurde die Stufe S2 in die systematische evidenzrecherchebasierte (S2e) oder strukturelle konsensbasierte Unterstufe (S2k) gegliedert. In der höchsten Stufe S3 vereinigen sich beide Verfahren. Diese Leitlinie entspricht der Stufe: S3.

Evidenzgraduierung
==================

Zur Graduierung der identifizierten Studien wurde in dieser Leitlinie das von der GRADE Working Group [@R8287722-1] ( [www.gradeworkinggroup.org](www.gradeworkinggroup.org) ) entwickelte System (GRADE = Grading of Recommendations Assessment, Development and Evaluation) angewendet ( [Tab. 2](#TB8287722DE-2){ref-type="table"} ).

###### 

**Tab. 2**  Schema der Evidenzgraduierung nach GRADE.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GRADE                    Beschreibung                                                                                                                                                                                           Symbol
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------
  hohe Qualität            Wir sind uns sehr sicher, dass der wahre Effekt nah an der Schätzung liegt.\                                                                                                                           ⊕⊕⊕⊕
                           *„We are very confident that the true effect lies close to that of the estimate of the effect."*                                                                                                       

  moderate Qualität        Wir sind uns relativ sicher mit der Abschätzung des Effekts: Der wahre Effekt liegt wahrscheinlich nah an der Schätzung, allerdings besteht auch die Möglichkeit eines substanziellen Unterschieds.\   ⊕⊕⊕⊖
                           *„We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different."*            

  niedrige Qualität        Unser Vertrauen in den Effektschätzer ist eingeschränkt: Der wahre Effekt könnte sich substanziell vom Effektschätzer unterscheiden.\                                                                  ⊕⊕⊖⊖
                           *„Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect."*                                                                  

  sehr niedrige Qualität   Wir haben nur sehr geringes Vertrauen in den Effektschätzer: Der wahre Effekt unterscheidet sich wahrscheinlich substanziell vom Effektschätzer.\                                                      ⊕⊖⊖⊖
                           *„We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect."*                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Empfehlungsgraduierung
======================

Die Methodik des Leitlinienprogramms Onkologie sieht eine Vergabe von Empfehlungsgraden durch die Leitlinienautoren im Rahmen eines formalen Konsensusverfahrens vor. Dementsprechend wurden strukturierte Konsensuskonferenzen durchgeführt [@R8287722-2] (Details im Leitlinienreport). Im Rahmen dieser Prozesse wurden die Empfehlungen von den stimmberechtigten Mandatsträgern formal abgestimmt.

In der Leitlinie werden zu allen evidenzbasierten Statements und Empfehlungen Angaben zur Evidenzgraduierung der zugrunde liegenden Studien sowie bei Empfehlungen zusätzlich die Stärke der Empfehlung (Empfehlungsgrad) ausgewiesen. Hinsichtlich der Stärke der Empfehlung werden in dieser Leitlinie entsprechend dem AWMF-Regelwerk [@R8287722-2] 3 Empfehlungsgrade unterschieden, die sich auch in der Formulierung der Empfehlungen jeweils widerspiegeln ( [Tab. 3](#TB8287722DE-3){ref-type="table"} ).

###### 

**Tab. 3**  Schema der Empfehlungsgraduierung.

  Empfehlungsgrad   Beschreibung        Ausdrucksweise
  ----------------- ------------------- ----------------
  A                 starke Empfehlung   soll
  B                 Empfehlung          sollte
  0                 Empfehlung offen    kann

Die Entscheidungskriterien für die Festlegung der Empfehlungsgrade werden im Leitlinienreport zu dieser Leitlinie erläutert.

Statements
==========

Als Statements werden Darlegungen oder Erläuterungen von spezifischen Sachverhalten oder Fragestellungen ohne unmittelbare Handlungsaufforderung bezeichnet. Sie werden entsprechend der Vorgehensweise bei den Empfehlungen im Rahmen eines formalen Konsensusverfahrens verabschiedet und können entweder auf Studienergebnissen oder auf Expertenmeinungen beruhen ( [Tab. 4](#TB8287722DE-4){ref-type="table"} ).

###### 

**Tab. 4**  Konsensstärke.

  Konsensstärke              prozentuale Zustimmung
  -------------------------- ------------------------------------
  starker Konsens            \> 95% der Stimmberechtigten
  Konsens                    \> 75 -- 95% der Stimmberechtigten
  mehrheitliche Zustimmung   \> 50 -- 75% der Stimmberechtigten
  Dissens                    \< 50% der Stimmberechtigten

Expertenkonsens (EK)
====================

Statements/Empfehlungen, für die eine Bearbeitung auf der Grundlage von Expertenkonsens der Leitliniengruppe beschlossen wurde, sind als Expertenkonsens ausgewiesen. Für die Graduierung der Expertenkonsens wurden keine Symbole bzw. Buchstaben verwendet, die Stärke des Konsenspunktes ergibt sich aus der verwendeten Formulierung (soll/sollte/kann) entsprechend der Abstufung in [Tab. 3](#TB8287722DE-3){ref-type="table"} .

IV  Leitlinie
=============

1  Differenzialdiagnostik und Abklärungsalgorithmus
===================================================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                                                                                                                                               GRADE
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  10.1.   Bei einem zytologischen Befund der Gruppe IIa sollte der behandelnde Gynäkologe darauf hingewiesen werden, dass in der Vergangenheit (2 Jahre) ein auffälliger Befund vorlag und die Patientin weiterhin beobachtet werden soll. Weitere differenzialdiagnostische Abklärungen sollen nur dann indiziert werden, wenn dies aufgrund der aktuellen Konstellation notwendig ist, um eine Überbehandlung zu vermeiden.   EK

1.1  Indikation zur Koloskopie in Abhängigkeit der Wahrscheinlichkeit für eine CIN 3
====================================================================================

  Nr.     Empfehlungen/Statements                                                                                                                                                   GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  10.2.   Die Indikation zur kolposkopischen Abklärung sollte ab einer Post-Test-Wahrscheinlichkeit für ein durchschnittliches kumulatives CIN-3+-Risiko von 10% gestellt werden.   EK

1.2  Welche Abklärungsmethoden sind geeignet bei auffälliger Zytologie?
=======================================================================

1.3  Welche Abklärungsmethoden sind geeignet bei positivem HPV-Test im Screening \> 30 Jahre?
=============================================================================================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.      Empfehlungen/Statements                                                                                                                                                           GRADE   Quellen
  -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  10.9.    Bei einem positiven HPV-Screeningtest sollte eine weiterführende zytologische Abklärung erfolgen.                                                                                 ⊕⊕⊖⊖\   [@R8287722-70] ,  [@R8287722-71] ,  [@R8287722-72] ,  [@R8287722-73] ,  [@R8287722-74] ,  [@R8287722-75] ,  [@R8287722-76] ,  [@R8287722-77] ,  [@R8287722-78] ,  [@R8287722-79]
                                                                                                                                                                                             B       

  10.10.   Bei einem positiven HPV-Screeningtest kann eine weiterführende Abklärung mittels p16/Ki-67-Testung erfolgen.                                                                      ⊕⊖⊖⊖\   [@R8287722-72] ,  [@R8287722-73]
                                                                                                                                                                                             0       

  10.11.   Bei einem positiven HPV-16/18 Testergebnis im HPV-basierten Screening sollte eine kolposkopische Abklärung erfolgen.                                                              ⊕⊖⊖⊖\   [@R8287722-77] ,  [@R8287722-79]
                                                                                                                                                                                             B       

  10.12.   Bei einem positiven HPV-Screeningtest und einem Befund ab II-p in der Abklärungszytologie bzw. im kombinierten HPV-Pap-Screening sollte eine kolposkopische Abklärung erfolgen.   EK      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2  Kolposkopie
==============

2.1  Einsatz der Abklärungskolposkopie
======================================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                        GRADE
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  11.1.   Die Kolposkopie soll nicht als Screeningmethode eingesetzt werden.                                                                                                                                                                             EK
  11.2.   Bei hohem Verdacht auf CIN 3+ bzw. ACis/Adeno-Ca (Risiko ≥ 10%\*) soll eine Abklärungskolposkopie durchgeführt werden,zur histologischen Sicherung von squamösen und glandulären Atypien/Neoplasien,zur Festlegung der operativen Strategie.   EK
  11.3.   Bei der Abklärungskolposkopie sollten bei Typ 1 und Typ 2 TZ kolposkopisch gesteuerte Biopsien aus der/den schwerstgradigen Läsion/en entnommen werden, bei Typ 3 TZ sollte eine endozervikale Curettage erfolgen.                             EK

2.2  Qualitätsmerkmale einer Abklärungskolposkopie bzw. einer Dysplasiesprechstunde
===================================================================================

  Nr.     Empfehlungen/Statements                                                                                                                                                       GRADE
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  11.4.   Die Kolposkopie soll als Abklärungskolposkopie in einer gemäß den Anforderungen der DKG/DGGG/AGO/AG-CPC/EFC zertifizierten Dysplasiesprechstunde/Dysplasieeinheit erfolgen.   EK

3  Versorgungsstrukturen
========================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                     GRADE
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  12.1.   An der seit 1971 empfohlenen Krebsfrüherkennungsuntersuchung (KFU) des Gebärmutterhalskrebses in Deutschland beteiligen sich jährlich ca. 50% der Frauen. Rund 70% der Frauen beteiligten sich an der Vorsorge mindestens einmal innerhalb eines 3-jährlichen Intervalls.   EK
  12.2.   Bei der deutschen Zervixkarzinom-Krebsfrüherkennungsuntersuchung (KFU) weisen Frauen mit niedrigem Sozialstatus und/oder hohem Alter eine geringere Teilnahmerate auf.                                                                                                      EK
  12.3.   Ein organisiertes Screening mit populationsbasierter Einladung und stringenter Qualitätssicherung kann zu einer effektiveren und sozial- wie altersbezogen ausgewogeneren Vorsorge führen.                                                                                  EK

4  Strategie bei Nichtinanspruchnahme der Vorsorge
==================================================

4.1  Einladungsschreiben
========================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                            GRADE   Quellen
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------- ----------------------------------------------------------------------------------------
  13.1.   Wiederholte Einladungsschreiben im Rahmen eines organisierten Screenings erhöhen die Teilnahmerate von den Frauen, welche die reguläre Früherkennungsuntersuchung nicht in Anspruch genommen haben, geringfügig.   ⊕⊕⊖⊖    [@R8287722-80] ,  [@R8287722-81] ,  [@R8287722-82] ,  [@R8287722-83] ,  [@R8287722-84]

4.2  HPV-Selbstabnahme
======================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.     Empfehlungen/Statements                                                                                                                                        GRADE   Quellen
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  13.2.   Mit dem HPV-Selbstabstrich lässt sich die Teilnahmerate bei den Frauen verdoppeln, die mittels Einladung nicht an der Krebsfrüherkennung teilgenommen haben.   ⊕⊕⊕⊖\   [@R8287722-85] ,  [@R8287722-86] ,  [@R8287722-87] ,  [@R8287722-88] ,  [@R8287722-89] ,  [@R8287722-90] ,  [@R8287722-91] ,  [@R8287722-92] ,  [@R8287722-93] ,  [@R8287722-94]
                                                                                                                                                                         B       

  13.3.   Diesen Frauen (Non-Respondern) sollte daher die Möglichkeit zum Selbstabstrich gegeben werden.                                                                 ⊕⊕⊕⊖\   [@R8287722-85] ,  [@R8287722-86] ,  [@R8287722-87] ,  [@R8287722-88] ,  [@R8287722-89] ,  [@R8287722-90] ,  [@R8287722-91] ,  [@R8287722-92] ,  [@R8287722-93] ,  [@R8287722-94]
                                                                                                                                                                         B       

  13.4.   Der HPV-Selbstabstrich im Screening soll den Frauen vorbehalten bleiben, die sich nicht an der Krebsvorsorgeuntersuchung beteiligen.                           ⊕⊕⊕⊖\   [@R8287722-89] ,  [@R8287722-95] ,  [@R8287722-96] ,  [@R8287722-97] ,  [@R8287722-98] ,  [@R8287722-99] ,  [@R8287722-100] ,  [@R8287722-101] ,  [@R8287722-102] ,  [@R8287722-103] ,  [@R8287722-104] ,  [@R8287722-105] ,  [@R8287722-106] ,  [@R8287722-107] ,  [@R8287722-108] ,  [@R8287722-109] ,  [@R8287722-110] ,  [@R8287722-111] ,  [@R8287722-112] ,  [@R8287722-113] ,  [@R8287722-114] ,  [@R8287722-115] ,  [@R8287722-116] ,  [@R8287722-117] ,  [@R8287722-118] ,  [@R8287722-119] ,  [@R8287722-120] ,  [@R8287722-121] ,  [@R8287722-122] ,  [@R8287722-123] ,  [@R8287722-124] ,  [@R8287722-125] ,  [@R8287722-126] ,  [@R8287722-127]
                                                                                                                                                                         A       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5  Therapie
===========

5.1  Geeignete Therapieverfahren für die Behandlung der squamösen und glandulären zervikalen intraepithelialen Neoplasien
=========================================================================================================================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   GRADE   Quellen
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- -------------------------------------------------------
  14.1.   Schlingenexzision und Laserexzision sollen die Methoden der Wahl für die Behandlung der squamösen und glandulären zervikalen intraepithelialen Neoplasie sein.                                                                                                                                                                                                                                                                                                                                                            ⊕⊖⊖⊖\   [@R8287722-128] ,  [@R8287722-129] ,  [@R8287722-130]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    A       

  14.2.   Die Messerkonisation kann bei der Behandlung glandulärer intraepithelialer Neoplasien als Alternative gewählt werden.                                                                                                                                                                                                                                                                                                                                                                                                     ⊕⊖⊖⊖\   [@R8287722-128]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    0       

  14.3.   Die Laservaporisation zur Behandlung von CIN 1, CIN 2 oder CIN 3 soll nach histologischer Abklärung durch Knipsbiopsien nur durchgeführt werden, wenn alle folgenden Bedingungen erfüllt sind:die komplette Transformationszone ist einsehbar (T-Zone Typ 1),kein Anhalt für Veränderungen des Drüsenepithels,kein Anhalt für ein invasives Geschehen,keine Diskrepanz zwischen zytologischer, kolposkopischer und histologischer Einschätzung der Biologie der Veränderung,die Patientin ist nicht älter als 50 Jahre.   EK      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5.2  Therapie unter kolposkopischer Kontrolle
=============================================

  Nr.     Empfehlungen/Statements                                                                                GRADE
  ------- ------------------------------------------------------------------------------------------------------ -------
  14.4.   Eine Therapie, ob Exzisions- oder Ablationsverfahren, soll unter kolposkopischer Kontrolle erfolgen.   EK

5.3  Management der CIN
=======================

6  Schwangerschaft
==================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                  GRADE
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  15.1.   Die Indikationen einer Kolposkopie (und ggf. Biopsie) im Rahmen einer Schwangerschaft sind dieselben wie die außerhalb einer Schwangerschaft.                                                                                                            EK

  15.2.   Eine Abklärung auffälliger Gebärmutterhalskrebsscreening-Befunde sollte während einer Schwangerschaft in einer DKG/AG-CPC-zertifizierten Dysplasiesprechstunde stattfinden.                                                                              EK

  15.3.   Eine endozervikale Kürettage soll während einer Schwangerschaft nicht durchgeführt werden.\                                                                                                                                                              EK
          Ein tiefer endozervikaler Abstrich sollte während einer Schwangerschaft nicht durchgeführt werden.                                                                                                                                                       

  15.4.   Schließt die Abklärung (zytologisch, kolposkopisch, ggf. histologisch) das Vorliegen einer hochgradigen Dysplasie und eines Karzinoms aus, sind weitere kolposkopische und/oder zytologische Untersuchungen in der Schwangerschaft nicht erforderlich.   EK
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6.1  Vorgehen bei CIN 2/3 oder ACIS in der Schwangerschaft
==========================================================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                    GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------
  15.5.   Während einer Schwangerschaft soll bei einer CIN 2/3 oder einem ACIS keine operative Therapie erfolgen, wenn das Vorliegen eines invasiven Karzinoms mit hoher Sicherheit ausgeschlossen wurde.                                            EK
  15.6.   Während einer Schwangerschaft sollen bei einer CIN 2/3 oder einem ACIS kolposkopische Kontrollen erfolgen. Das Intervall sollte 3 Monate betragen.                                                                                         EK
  15.7.   Nur wenn in der Schwangerschaft ein invasives Karzinom durch Zytologie, Kolposkopie und Biopsie nicht mit hoher Sicherheit ausgeschlossen werden kann, besteht die Indikation zur histologischen Abklärung durch ein Exzisionsverfahren.   EK

6.2  Geburtsmodus bei CIN 2/3
=============================

  Nr.     Empfehlungen/Statements                                                                                              GRADE
  ------- -------------------------------------------------------------------------------------------------------------------- -------
  15.8.   Das Vorliegen einer CIN 2/3 soll keinen Einfluss auf die Entscheidungsfindung hinsichtlich des Geburtsmodus haben.   EK

6.3  Geburtshilfliche Komplikationen nach CIN-Therapie
======================================================

  Nr.      Empfehlungen/Statements                                                                                                                                                                                                             GRADE
  -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  15.9.    Exzisionsverfahren in der Schwangerschaft sind mit erheblichen geburtshilflichen Risiken wie Frühgeburt assoziiert. Vorangegangene Exzisionsverfahren sind auch für nachfolgende Schwangerschaften mit diesen Risiken assoziiert.   EK
  15.10.   Da die Messerkonisation mit dem höchsten geburtshilflichen Risiko assoziiert ist, soll sie bei Frauen mit noch nicht abgeschlossener Familienplanung nicht durchgeführt werden.                                                     EK

7  Nachbetreuung
================

7.1  HPV-Test und Zytologie in der Nachbetreuung nach Therapie einer CIN
========================================================================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.     Empfehlungen/Statements                                                                                                                GRADE   Quellen
  ------- -------------------------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  16.1.   In der Nachbetreuung nach Therapie einer CIN/ACIS soll eine kombinierte Untersuchung mit HPV-Test und Zytologie durchgeführt werden.   ⊕⊕⊖⊖\   [@R8287722-131] ,  [@R8287722-132] ,  [@R8287722-133] ,  [@R8287722-134] ,  [@R8287722-135] ,  [@R8287722-136] ,  [@R8287722-137] ,  [@R8287722-138] ,  [@R8287722-139] ,  [@R8287722-140] ,  [@R8287722-141] ,  [@R8287722-142] ,  [@R8287722-143] ,  [@R8287722-144] ,  [@R8287722-145] ,  [@R8287722-146]
                                                                                                                                                 A       

  16.2.   Bei auffälligen Befunden (mindestens 1 Testverfahren positiv) sollte eine differenzierte Kolposkopie durchgeführt werden.              ⊕⊕⊖⊖\   [@R8287722-131] ,  [@R8287722-132] ,  [@R8287722-133] ,  [@R8287722-134] ,  [@R8287722-135] ,  [@R8287722-136] ,  [@R8287722-137] ,  [@R8287722-138] ,  [@R8287722-139] ,  [@R8287722-140] ,  [@R8287722-141] ,  [@R8287722-142] ,  [@R8287722-143] ,  [@R8287722-144] ,  [@R8287722-145] ,  [@R8287722-146]
                                                                                                                                                 B       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

7.2  Stellenwert der Biomarker in der Nachbetreuung nach CIN-Therapie
=====================================================================

8  Komplementäre, alternative und integrative Medizin
=====================================================

8.1  Alternativmedizinische Diagnostik
======================================

  Nr.     Empfehlungen/Statements                                                                                                                   GRADE
  ------- ----------------------------------------------------------------------------------------------------------------------------------------- -------
  17.1.   Eine alternativmedizinische Diagnostik bei der Erkennung von Zervixdysplasien oder einer Disposition dazu soll nicht eingesetzt werden.   EK

8.2  Alternativmedizinische Therapie
====================================

  Nr.     Empfehlungen/Statements                                                       GRADE
  ------- ----------------------------------------------------------------------------- -------
  17.2.   Die alternativmedizinische Therapie von Dysplasien sollte abgelehnt werden.   EK

8.3  Komplementärmedizinische Therapie
======================================

  Nr.     Empfehlungen/Statements                                                                                                            GRADE
  ------- ---------------------------------------------------------------------------------------------------------------------------------- -------
  17.3.   Komplementärmedizinische Behandlungsempfehlungen lassen sich aufgrund des Mangels an aussagekräftigen Studien nicht aussprechen.   EK

9  Aufklärung und Information, Umgang mit psychischer Belastung
===============================================================

9.1  Aufklärung und Information von Teilnehmerinnen an der Zervixkarzinomfrüherkennung
======================================================================================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                         GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  18.1.   Bei der Aufklärung von Teilnehmerinnen an der Früherkennung des Zervixkarzinoms sollen folgende Aspekte berücksichtigt werden:Erklärung der Krankheit,natürlicher Infektionsverlauf bei HPV und der assoziierten Zellveränderungen,die verschiedenen HPV-Typen,Risikofaktoren für das Zervixkarzinom,Auswirkung auf Partner,Beschreibung der Früherkennungsmaßnahme,Angaben zu Nutzen und Schaden der Früherkennungsmaßnahme,Angaben zur Qualität der Früherkennungsmaßnahme.   EK

9.2  Aufklärung über die Diagnose, Behandlungsmöglichkeiten und Nachbetreuung
=============================================================================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                     GRADE
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  18.2.   Aufklärungsinhalte für Frauen mit abklärungsbedürftigem Screeningbefund sollen folgende Erläuterung enthalten:BefundergebnisseDifferenzialdiagnostikTherapieoptionenangestrebte BehandlungszieleDauer und die Durchführung der einzelnen TherapiemaßnahmenNotwendigkeit zur Nachbetreuung   EK

10  Kosteneffektivität
======================

  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                                                                                               GRADE   Quellen
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------
  19.1.   Ein HPV-basiertes Screening alle 3 Jahre besitzt ein relativ günstiges Schaden-Nutzen-Verhältnis. Es erzeugt im Vergleich zum jährlichen zytologischen Screening einen vergleichbaren erwarteten Nutzen bei geringerem erwarteten Schaden (z. B. operative Eingriffe, Kolposkopien, psychische Belastung durch auffällige Befunde und Nachfolgeuntersuchungen).       ⊕⊖⊖⊖    \[s. Leitlinienreport und Evidenzbericht\]
  19.2.   Ein HPV-basiertes Screening mit Intervallen von 3 -- 5 Jahren ist in Deutschland als kosteneffektiv zu bewerten. HPV-basierte Screeningverfahren mit Intervallen von 2 Jahren haben ein ungünstigeres Kosteneffektivitätsverhältnis. Screeningverfahren mit jährlichen Intervallen erhöhen deutlich die Kosten, ohne einen maßgeblichen Zusatznutzen zu generieren.   ⊕⊖⊖⊖    [@R8287722-158]
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